PLoS ONE (Jan 2019)

Graft glycocalyx degradation in human liver transplantation.

  • Arie Passov,
  • Alexey Schramko,
  • Heikki Mäkisalo,
  • Arno Nordin,
  • Sture Andersson,
  • Eero Pesonen,
  • Minna Ilmakunnas

DOI
https://doi.org/10.1371/journal.pone.0221010
Journal volume & issue
Vol. 14, no. 8
p. e0221010

Abstract

Read online

ObjectiveIschaemia/reperfusion-injury degrades endothelial glycocalyx. Graft glycocalyx degradation was studied in human liver transplantation.MethodsTo assess changes within the graft, blood was drawn from portal and hepatic veins in addition to systemic samples in 10 patients. Plasma syndecan-1, heparan sulfate and chondroitin sulfate, were measured with enzyme-linked immunosorbent assay.ResultsDuring reperfusion, syndecan-1 levels were higher in graft caval effluent [3118 (934-6141) ng/ml, P = 0.005] than in portal venous blood [101 (75-121) ng/ml], indicating syndecan-1 release from the graft. Concomitantly, heparan sulfate levels were lower in graft caval effluent [96 (32-129) ng/ml, P = 0.037] than in portal venous blood [112 (98-128) ng/ml], indicating heparan sulfate uptake within the graft. Chondroitin sulfate levels were equal in portal and hepatic venous blood. After reperfusion arterial syndecan-1 levels increased 17-fold (P ConclusionSyndecan-1 washout from the liver indicates extensive glycocalyx degradation within the graft during reperfusion. Surprisingly, heparan sulfate was taken up by the graft during reperfusion. Corroborating previous experimental reports, this suggests that endogenous heparan sulfate might be utilized within the graft in the repair of damaged glycocalyx.